Ligand validation:3QX3

EVP: (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside

EVP is a Ligand Of Interest in 3QX3 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3QX3_EVP_D_1	91%	2%	0.09	0.975	4.22	2.32	23	25	1	0	100%	1
3QX3_EVP_A_1	90%	2%	0.082	0.963	4.39	2.29	26	24	0	0	100%	1
5ZRF_EVP_D_101	81%	1%	0.118	0.972	5.6	1.78	26	14	6	0	100%	1
5CDP_EVP_H_2101	58%	37%	0.139	0.917	0.78	1.68	1	12	1	0	100%	1
5CDN_EVP_N_2101	58%	32%	0.171	0.949	0.77	1.91	1	12	0	0	100%	1
4LB9_EVP_A_605	46%	2%	0.108	0.84	3.83	2.93	18	33	3	0	100%	1
5GWK_EVP_D_102	20%	1%	0.294	0.901	4.58	2.68	25	28	2	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.